摘要:肝纤维化是继发于各种慢性肝损伤之后组织修复过程中的代偿反应,其发病实质是肝内细胞外基质(Extracellular matrix, ECM)合成大于降解,最终导致ECM过度沉积。研究发现肝纤维化发展过程中伴随有大量炎性介质和活性氧的产生,从而导致肝脏发生炎症反应。肝星状细胞(Hepatic stellate cell,HSC)的活化是肝纤维化发展的中心环节,通过药物干预HSC的生物学行为能够有效防治肝纤维化。本文从肝纤维化概述、炎症与肝纤维化、千层纸素A在防治肝纤维化中的作用等方面综述了千层纸素A在肝纤维化中的作用及研究进展。
关键词:肝纤维化;千层纸素A;炎症;肝星状细胞;作用机制
Abstract: Liver fibrosis is a compensatory response secondary to tissue repair after various chronic liver injury. The essence of liver fibrosis is the synthesis more than degradation of ECM, resulting in the excessive deposition of ECM. Research have reported that massive inflammatory factors and reactive oxygen species generate in the process of liver fibrosis, which causes inflammatory reactions in liver. The activation of hepatic stellate cells (HSCs) is the central link in liver fibrosis. Many researchers found that drug can effectively prevent biological behaviors of HSC during liver fibrosis. This paper reviewed the overview of liver fibrosis, the relationship between inflammation and liver fibrosis, the role of Qroxylin A in the prevention and treatment of liver fibrosis.
Key words: Liver fibrosis; Qroxylin A; Inflammation; Hepatic stellate cells; Mechanism
肝纤维化(Liver fibrosis)作为慢性肝病发展为肝硬化必经的病理过程,对其有效防治仍是困扰世界医学界的重大难题[1-2]。肝纤维化的发病实质是肝内细胞外基质(Extracellular matrix, ECM)合成大于降解,最终导致ECM过度沉积[3]。如无有效的治疗措施,随着病情的发展将导致肝脏纤维结节形成并破坏正常的肝脏结构与功能,最终发展成为肝硬化而出现肝脏功能的衰退,甚至演变为肝癌[4]。此外,炎症微环境与肝纤维化关系密切,肝纤维化发生发展的同时常伴随着炎症的发生,而炎症又会影响肝纤维化、肝硬化和肝癌的发展进程,是慢性肝病最重要的特征之一[5-8]。目前,尚缺少疗效确切的治疗肝纤维化药物和手段。因此,需要有更多新的有效的防治药物和策略[9]。近年来,应用天然药物治疗肝纤维化越来越被广泛接受。本文将就近几年来这方面的研究进展,论述千层纸素A通过调控炎症微环境改善肝纤化机制研究。
1肝纤维化概述
课题毕业论文、文献综述、任务书、外文翻译、程序设计、图纸设计等资料可联系客服协助查找。